Lipoxin Mediated Neuroprotection

Tech ID: 27404 / UC Case 2017-109-0

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 11,439,615 09/13/2022 2017-109
Canada Published Application 2017-109
 

Additional Patent Pending

Brief Description

This is small molecule neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.  

Suggested uses

Therapeutic treatment with LXB4 is efficacious in both pathological and functional measures in a chronic glaucoma model. Together, these results indicate a novel resident neuroprotective mechanism for LXB4 that can become deficient following neuronal injury. Restoration of this balance suggests a therapeutic potential. 

Advantages

The role and regulation of labile small molecule factors in neuroinflammation and neurodegeneration is not well understood. This small molecule has neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.  

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Flanagan, John G.

Other Information

Keywords

Retinal, Glaucoma

Categorized As